Meridian Bioscience Inc

Find Ratings Reports
VIVO : NASDAQ : Health Care
$20.48 up 0.08 | 0.39%
Today's Range: 20.32 - 20.49
Avg. Daily Volume: 209,600
07/27/16 - 3:59 PM ET

Financial Analysis


MERIDIAN BIOSCIENCE INC's gross profit margin for the second quarter of its fiscal year 2016 is essentially unchanged when compared to the same period a year ago. Sales and net income have dropped, underperforming the average competitor within its industry. MERIDIAN BIOSCIENCE INC is extremely liquid. Currently, the Quick Ratio is 3.83 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year.

During the same period, stockholders' equity ("net worth") has increased by 5.43% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q2 FY16 Q2 FY15
Net Sales ($mil)51.2651.55
EBITDA ($mil)17.6217.07
EBIT ($mil)16.3615.73
Net Income ($mil)9.0910.07


Balance Sheet Q2 FY16 Q2 FY15
Cash & Equiv. ($mil)48.9542.72
Total Assets ($mil)258.36178.31
Total Debt ($mil)59.840.0
Equity ($mil)169.85161.1


Profitability Q2 FY16 Q2 FY15
Gross Profit Margin67.9665.68
EBITDA Margin34.3733.11
Operating Margin31.9130.52
Sales Turnover0.751.08
Return on Assets13.7619.62
Return on Equity20.9321.71
Debt Q2 FY16 Q2 FY15
Current Ratio6.037.65
Debt/Capital0.260.0
Interest Expense0.040.0
Interest Coverage380.420.0


Share Data Q2 FY16 Q2 FY15
Shares outstanding (mil)42.0841.71
Div / share0.20.2
EPS0.210.24
Book value / share4.043.86
Institutional Own % n/a n/a
Avg Daily Volume216983.0248262.0

Valuation


BUY. The current P/E ratio indicates a significant discount compared to an average of 62.82 for the Health Care Equipment & Supplies industry and a value on par with the S&P 500 average of 25.05. Conducting a second comparison, its price-to-book ratio of 5.01 indicates a significant premium versus the S&P 500 average of 2.81 and a premium versus the industry average of 4.84. The current price-to-sales ratio is well above the S&P 500 average, but below the industry average. The valuation analysis reveals that, MERIDIAN BIOSCIENCE INC seems to be trading at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
VIVO 24.10 Peers 62.82   VIVO 20.62 Peers 33.31

Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations.

VIVO is trading at a significant discount to its peers.

 

Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

VIVO is trading at a significant discount to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
VIVO 21.53 Peers 29.14   VIVO 10.26 Peers 1.03

Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations.

VIVO is trading at a discount to its peers.

 

Premium. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

VIVO trades at a significant premium to its peers.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
VIVO 5.01 Peers 4.84   VIVO 0.00 Peers 159.18

Average. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

VIVO is trading at a valuation on par with its peers.

 

Neutral. Higher earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

The growth rate for VIVO is not available.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
VIVO 4.40 Peers 4.71   VIVO 0.11 Peers 20.16

Average. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

VIVO is trading at a valuation on par with its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

VIVO significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades